Headed by a consultant biostatistician with over 25 years of experience in the pharmaceutical industry, Stone Biostatistics provides innovative solutions in optimising drug development programmes specialising in oncology.

•

​Andrew Stone is a former head of the Biometrics oncology TA at AstraZeneca and has significant regulatory experience, leading biostatistics teams to the submission or approval of six oncology products